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Abstract
Background: Adult and adolescent vaccination rates are far below coverage targets in the United States. Our
objective was to identify the most influential factors related to vaccine uptake among adults, adolescents, and
parents of adolescents (parents) in the United States.
Methods: We used a fractional factorial design to create a binary choice survey to evaluate preferences for vaccination.
The national survey was fielded to a sample of adults, adolescents ages 13–17 years, and parents, using a national
probability-based online research panel in November 2015. Respondents were presented with 5 profiles of a
hypothetical vaccine and asked in a series of questions whether they would accept each vaccine. We analyzed
the binary choice data using logistic regression in STATA v13 (College Station, TX) to calculate the odds that a
participant would choose to accept the vaccine.
Results: We received completed responses from 334 (51%) of 652 adults, 316 (21%) of 1516 adolescents, and 339
(33%) of 1030 parents. Respondents were generally representative of the U.S. population. Vaccine effectiveness
was the most influential factor in the choice to vaccinate for all groups. Other most influential factors were primary care
provider (PCP) recommendation and the out-of-pocket cost of the vaccine. Other factors such as risk of illness, risk of
vaccine side effects, vaccination location, and time for vaccination were not important in the decision to get vaccinated.
Conclusions: Adults, adolescents, and parents are most sensitive to vaccine effectiveness, PCP recommendation, and
out-of-pocket cost for vaccination in their decision to get vaccinated. Strong PCP recommendations that focus on
vaccine effectiveness and health care policies that minimize out-of-pocket costs for vaccinations may increase
vaccine uptake by adults and adolescents.
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Introduction
Achieving target coverage rates for many adolescent and
adult vaccines remains a public health challenge in the
United States. Vaccination rates for influenza, human
papillomavirus (HPV), varicella, and hepatitis B have
fallen short of national immunization goals in recent
years. [1] [2, 3]. Previous research has identified numerous
factors influencing vaccine uptake, including knowledge of
the vaccine and illness [4, 5], physician recommendation
[5–8], perception of the vaccine’s effectiveness [6, 9], risk
of illness [7, 10], and community approval [11, 12]. How-
ever, these studies narrowly focused on specific popula-
tions such as women or racial/ethnic minority groups or
specific vaccines such as the HPV vaccine, all of which are
known to have context-specific factors influencing vaccine
uptake. It is not clear from prior research how these nar-
rowly focused studies generalize into factors that impact
vaccine acceptance more broadly, and how important
each of these factors are in vaccination decision-making.
In addition, while the decision to vaccinate adolescents
is often influenced by preferences of both adolescents
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and their parents, particularly among older adolescents
and for HPV vaccination [13], only a small number of
studies have included an adolescent perspective [14, 15].
Identifying the most influential factors in adult, adoles-
cent, and parent vaccination decisions could help public
health professionals design more effective programs to
increase vaccination rates.
Increasingly, stated-preference methods are used to
identify the relative importance of factors or attributes
associated with health programs [16–18]. Choice experi-
ments elicit preferences by asking respondents whether
they would choose an attribute-based description of a
service or program. The choices and trade-offs that
respondents make can be used to infer the relative
importance of each attribute and can be a powerful tool
to help policy makers design programs that are aligned
with patient preferences. The goal of this study was to
identify the most important factors related to vaccine
decision-making among U.S. adults, adolescents, and
parents of adolescents (parents) using a stated pre-
ference binary choice experiment.
Methods
Survey development
We conducted two-hour interviews with each of four
focus groups using a standardized interview guide in
Boston, MA and Ann Arbor, MI in 2013 to identify attri-
butes that could be used to create hypothetical vaccination
profiles in a preference survey. To include a diversity of
perspectives, one group was comprised of Spanish-
speaking adults (n = 10, including both parents and non-
parents; ages 18–64 years), one of English-speaking adults
(n = 9), one of English-speaking adolescents (n = 7, ages
13–17 years), and one of parents (n = 6).
During the focus group interviews, participants were
asked to describe their experience with vaccination, and
factors that were important to them in their decision to
vaccinate. At the end of the focus group, they were
asked to rank factors relevant in their decision to vaccin-
ate from most to least important. We used this ranking
data from the focus groups along with relevant literature
and expert opinion to identify 12 factors that impact
vaccine uptake among parents, adults and adolescents
(e.g., out-of-pocket cost of vaccine; Table 1) and assign
2–8 levels to each factor that represented possible values
(e.g., out-of-pocket cost: $10, $25, etc.; Additional file 1:
Table S1). These factors and levels were the basis for
creating vaccination profiles in the preference survey.
Levels were chosen to represent meaningful differences
within attributes, with a range of values that were relevant
for current or anticipated future vaccine decision-making
scenarios based on our literature review and expert
opinion. Further adjustments were made to the levels
during pretesting if respondents indicated that some levels
were not meaningfully different. We derived two descrip-
tive attributes (risk of illness with vaccination, risk of
death with vaccination; Additional file 2: Table S2) with 16
levels in each to help respondents understand how the
risk of illness and death would change with vaccination,
depending on the effectiveness of the vaccine (included in
the survey as 20%, 70%, 95%, and 99% relative risk
Table 1 Attributes and definitions for adult respondents a
Attribute Definition
Seriousness of illness This is how bad or serious the illness
would be for you if you got sick.
Duration of illness This is how long you would have
symptoms of the illness if you got sick.
Vaccine effectiveness This is the likelihood that you will NOT get
the illness that the vaccine can prevent if
you are vaccinated. Vaccines with greater
effectiveness are better at reducing your
risk of illness and death.
Your risk of illness without
vaccination
This is the likelihood you will get the
illness that the vaccine can prevent if you
are not vaccinated.
Your risk of death
without vaccination
This is the likelihood you will die from the
illness that the vaccine can prevent if you
are not vaccinated.
Your risk of severe side
effect from vaccination
This is the likelihood that after vaccination,
you will get a serious long-term or
permanent disability that affects your
nervous system. You would no longer be
able to do daily activities because of the
side effect. The side effect is caused by
what is in the vaccine.
Length of time vaccine
has been available
This is the number of years that the
vaccine has been available to the public in
the United States.
Location This is the place you go to get vaccinated.
Time This is the total time it would take you to
get one shot of the vaccine, including:
(1) Time you wait
(2) Time you spend with the health care
professional (3) Travel time to and from the
location where you get the vaccine.
Type of health care
professional giving
vaccine
This is the type of healthcare professional
who gives you the vaccine.
Primary care provider
recommendation
This is the recommendation of your
primary care provider about getting the
vaccine. A primary care provider is the
person you see for regular medical care
and can be a doctor, a nurse practitioner
(NP) or a physician assistant (PA).
Cost after insurance This is the amount that your family would
pay for you to receive the vaccine. This
amount would not be covered by
insurance. You would be paying with
money that you have available today.
aAttributes were the same for adolescents and parents, but definitions differed
slightly. Additional attributes included risk of illness with vaccination and risk
of death with vaccination which were derived by multiplying the risk of
illness/death without vaccination by the vaccine effectiveness. These
additional attributes and their levels are available in Additional file 2: Table S2
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reduction). Risk of illness with vaccination was derived by
multiplying the risk of illness without vaccination by the
vaccine effectiveness. Risk of death with vaccination was
derived by multiplying the risk of death without vacci-
nation by the vaccine effectiveness. The use of visual aids
has been strongly recommended for experiments of this
type [19]. Therefore, pictographs were created to improve
respondent comprehension of risk information with and
without vaccination (Fig. 1) [20].
We developed three versions of a vaccine preference
survey, one each for adults, adolescents, and parents.
Attributes were the same across the survey versions, but
the wording of definitions was adjusted as appropriate
(e.g., school for adolescents versus work for adults). The
survey included an introduction to the 12 attributes, their
definitions, and levels, as well as a practice question to
orient the respondent to the task. The respondent was
then presented with 5 hypothetical vaccine partial profiles
with 8 of the 12 attributes in each.
For each of the 5 profiles that they saw, respondents
were asked a binary choice question and a best-worst
scaling question. We chose for respondents to see one
profile at a time to allow us to use both of these
methods together. The binary choice (yes/no) question
came before each profile; we asked adult and adolescent
respondents about whether they would choose to get a
vaccine for themselves (Fig. 1). Parents were asked about
vaccinating their adolescent child. Also, in each profile,
respondents were asked to choose the most important
and least important factors in their decision to receive
or not receive the vaccine (Fig. 1). Only data from the
binary choice question were used for this analysis.
The partial profile design always included the “vaccine
effectiveness” attribute in all profiles with randomly
assigned levels. Of the remaining 11 attributes, we chose
7 to vary in each profile. The process of identifying the 7
to vary in each profile was based on a fractional factorial
design [21] that ensured attribute balance and statistical
Fig. 1 Sample conjoint analysis question for adult respondent
Lavelle et al. Journal of Patient-Reported Outcomes            (2019) 3:51 Page 3 of 12
efficiency. [22] This design ensures the best orthogonal
combination of attribute levels to minimize correlation
between attributes and levels. We evaluated the per-
formance of the design with the D-efficiency statistic,
which provides a means of evaluating the most efficient
combination of choice sets based on balance and orthog-
onality [23]. Sixty-five profiles were created in this
process. Divided into 13 blocks of 5 profiles, and each
respondent was randomized to one of these blocks. Prior
to survey administration, we manually screened all
profiles for logical consistency.
At the end of the survey, we collected respondents’
health insurance status, general health status, confidence
in their responses, and attitudes and behaviors con-
cerning vaccines (Table 2). The online survey vendor
also collected respondents’ demographic information
and whether they had Internet access prior to joining
the research panel, which is an indication of otherwise
unmeasured socio-economic factors.
Survey administration
Prior to fielding, we conducted cognitive pretests with
adults, adolescents, and parents (n = 38) to ensure respon-
dents understood the survey questions as intended, and
that derived attributes and visualizations were effective in
conveying the relationship between vaccine effectiveness
and risks of illness and death with and without vacci-
nation. We also used these pretests to determine whether
profiles could be presented to respondents with all 12
attributes. This process highlighted the cognitive burden
of considering 12 attributes at once, and therefore we
created partial profiles with 8 attributes. We ensured that
participants could answer 5 choice questions without
cognitive difficulty, and in the timeframe acceptable for
our survey. We conducted a national pilot of the survey
(n = 150) in October 2015 (data not shown).
In November 2015, we administered the final survey
to a national sample of 652 adults, 1516 adolescents,
and 1030 parents using KnowledgePanel (GfK Custom
Research, LLC, New York, NY), a probability-based
online research panel [24]. KnowledgePanel members
receive a small cash incentive for each survey they
complete and computer and Internet access, if needed,
while participating in surveys. Adults who were also the
parent of an adolescent were eligible for either the adult
or the parent survey but could only be chosen once to
answer in either capacity.
Analysis
Using the binary choice data, we used logistic regression
to calculate the odds that a respondent would choose to
receive (or have their adolescent child receive) the
vaccine described in the profile. The dependent variable
was whether the respondent chose to accept or decline
the vaccine in the profile, and each factor-level seen in
that profile was coded as an independent variable using
effect coding. With effect coding the estimated inde-
pendent effects for each attribute level, including the ref-
erence level, represent the incremental effect over the
mean for all respondents [25]. We controlled for re-
spondent characteristics including respondent gender,
age, U.S. region, race/ethnicity, household income, edu-
cation level, employment (adults and parents only), and
previous experience with a vaccine side effect.
The resulting log odds parameter estimates for each
attribute-level in the model represent the relative strength
of the respondent’s preference of that level compared to
the mean effect. Positive levels that are significantly
greater than zero indicate that respondents were more
likely to choose a profile with that level relative to the
mean, and negative levels that are significantly lower than
zero indicate that respondents were less likely to choose a
profile with that level relative to the mean. Confidence
intervals (CIs) for parameter estimates that include zero
indicate no difference from the mean effect at the 5% sig-
nificance level.
If the CIs for levels within an attribute do not overlap,
the levels are statistically different (p < 0.05) from each
other. A significant difference between attribute-level co-
efficients can be interpreted as the change in preference
for vaccination between these two levels, conditional on
the other attribute-levels included in the survey.
We clustered standard errors using generalized esti-
mating equations to adjust for multiple answers per
respondent [26]. We stratified analyses by respondent type
(adult, adolescent, or parent). We reviewed how predicted
probabilities of uptake varied under different scenarios.
In sensitivity analyses we excluded: 1) respondents
who reported they were not confident in their responses
and 2) those that always accepted or always declined the
vaccine profile presented to them. In another sensitivity
analysis we include out-of-pocket cost in our model as a
continuous variable instead of a categorical variable. We
also explored two alternative model specifications that
included terms for the absolute risk reduction due to
vaccination in each profile (baseline risk x vaccine effect-
iveness). In the first model we added interaction terms
to the model between vaccine effectiveness, and risk of
illness and death (Additional file 7: Table S7). In the sec-
ond model we added two calculated parameters for the
absolute risk reduction of illness and death with vaccin-
ation and removed variables for vaccine effectiveness
and baseline risk of illness and death from the model
specification (Additional file 7: Table S7).
All analyses were performed in 2016 using STATA v13
(College Station, TX). The study was approved by the
University of Michigan Health System Institutional
Review Board.
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Table 2 Respondent demographics, confidence in responses, and vaccination practices and beliefs
Adults (n = 334)
n (%)
Adolescents (n = 316)
n (%)
Parents (n = 339)
n (%)
Gender
Female 153 (45.8) 171 (54.1) 161 (47.5)
Age
13–15 0 149 (47.2) 0
16–17 0 167 (52.9) 0
18–29 63 (18.9) 0 5 (1.5)
30–49 133 (39.8) 0 234 (69.0)
50–64 138 (41.3) 0 100 (29.5)
Education
Less than high school 19 (5.7) 316 (100) 17 (5.0)
High school/Some college 183 (54.8) 0 161 (47.5)
Bachelor’s degree or higher 132 (39.5) 0 161 (47.5)
Race/Ethnicity
White, non-Hispanic 255 (76.4) 169 (53.5) 247 (72.9)
Black, non-Hispanic 23 (6.9) 30 (9.5) 18 (5.3)
Other, non-Hispanic 27 (8.1) 43 (13.6) 25 (7.4)
Hispanic 7 (2.1) 74 (23.4) 49 (14.6)
Region
Northeast 64 (19.2) 30 (9.5) 65 (19.2)
Midwest 83 (24.9) 91 (28.8) 88 (26.0)
South 119 (35.6) 112 (35.4) 120 (35.4)
West 68 (20.4) 83 (26.3) 66 (19.5)
Household income
< $25,000 59 (17.7) 63 (19.9) 28 (8.3)
$25,000–$49,999 56 (16.8) 75 (23.7) 43 (12.7)
$50,000–$99,999 112 (33.6) 108 (34.1) 129 (38.1)
> $100,000 107 (32.1) 70 (22.1) 139 (41.0)
Marital Status
Divorced/Separated/Widowed 51 (15.3) 0 31 (9.2)
Married/Living with partner 198 (59.3) 0 301 (88.8)
Never married 85 (25.5) 316 (100) 7 (2.1)
Employment Status
Employed 234 (70.1) NA 261 (77.0)
Not employed 100 (29.9) 78 (22.9)
Insurance
Private 233 (71.0) 136 (43.3) 262 (78.4)
Medicaid 53 (16.1) 76 (24.2) 58 (17.4)
Have insurance, unsure of type 8 (2.4) 82 (26.1) 4 (1.2)
Do not have insurance 19 (5.8) 9 (2.9) 3 (0.9)
Other 15 (4.6) 11 (3.5) 7 (2.1)
Confidence in conjoint survey questions
Very/somewhat confident 297 (89.5) 279 (88.6) 311 (92.6)
Not confident/guess 35 (10.5) 36 (11.4) 25 (7.4)
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Results
Sample
We analyzed completed surveys from 334 (51%) adults,
316 (21%) adolescents, and 339 (33%) parents. Respon-
dents were generally representative of the U.S. population,
with the exceptions that adults surveyed were more likely
to be college educated, white, and married, adolescents
were more likely to be Hispanic and lower income, and
parents were more likely to be educated and white, com-
pared to Census averages (Table 2, additional demographic
information is given in Additional file 3: Table S3). Fifty
three percent of adults, 77% of adolescents, and 90% of
parents reported being in excellent or very good health.
Approximately half of respondents in each group reported
having received a vaccination within the past year.
Choice to accept or decline vaccination
Among adults, adolescents, and parents, the choice of
whether to accept or decline the vaccine presented in the
profile was primarily driven by three factors: vaccine
effectiveness, primary care provider (PCP) recommenda-
tion, and the out-of-pocket cost of the vaccine (Fig. 2a-c;
Additional file 4: Table S4). Vaccine effectiveness was the
most influential factor for all groups. For adults, there was
a statistically significant increase in preference between
vaccines that offered 20% effectiveness, which respondents
were less likely to choose, and vaccines that offered 70%
effectiveness, which respondents were more likely to
choose (Fig. 2a). Gains in effectiveness above 70% did not
significantly increase respondent preferences. For ado-
lescents, there was a statistically significant increase in
preference between vaccines with 20% effectiveness,
which they were less likely to choose, and those with
99% effectiveness, which adolescents were more likely
to choose (Fig. 2b). Vaccine effectiveness of 70% or 95%
effectiveness did not impact adolescent choice. Parents
were less likely to choose vaccines with 20% and 70%
effectiveness, and more likely to choose vaccines with
99% effectiveness, but were indifferent to vaccines with
95% effectiveness (Fig. 2c).
Among adults, the next most influential factor in their
decision to vaccinate following vaccine effectiveness was
out-of-pocket cost. The large significant decrease in pre-
ference between vaccines that cost $10 at the lowest level
and $1000 at the highest level was primary influenced by a
statistically significant decrease in preferences between
vaccines that cost $10 vs. $100 and again between vaccines
that cost $100 vs. $1000 (Fig. 2a). Among adolescents and
parents, preferences based on out-of-pocket cost did not
follow the expected ordering; the only significant decrease
in adolescent preferences came from increase in cost from
$100 to $1000 (Fig. 2b), and the only significant decrease
in parent preferences came from an increase in cost from
$25 to $50 (Fig. 2c). Two sensitivity analyses that included
cost and log cost as continuous model variables showed a
statistically significant decrease in preference associated
with increasing out-of-pocket cost in all groups (results
not shown).
Table 2 Respondent demographics, confidence in responses, and vaccination practices and beliefs (Continued)
Adults (n = 334)
n (%)
Adolescents (n = 316)
n (%)
Parents (n = 339)
n (%)
In general, would you say your/ your child’s health is
Excellent/very good 177 (53.3) 240 (76.7) 302 (89.6)
Good 118 (35.5) 56 (17.9) 28 (8.3)
Fair/Poor 37 (11.1) 17 (5.4) 7 (2.1)
I believe it is important to be/to have my child vaccinated
Always/mostly agree 195 (58.7) 215 (68.7) 276 (81.9)
Sometimes agree, sometimes disagree 99 (29.8) 74 (23.6) 46 (13.7)
Always/mostly disagree 38 (11.5) 24 (7.7) 15 (4.5)
I believe the benefits of vaccines outweigh risks
Always/mostly agree 192 (58.5) 188 (61.0) 252 (75.5)
Sometimes agree, sometimes disagree 108 (32.9) 96 (31.1) 70 (21.0)
Always/mostly disagree 28 (8.5) 24 (7.8) 12 (3.4)
Last time you/your child was vaccinated
< 1 year ago 158 (47.3) 157 (49.7) 173 (51.0)
1–5 years ago 85 (25.5) 129 (40.8) 145 (42.8)
> 5 years ago 85 (25.5) 29 (9.2) 18 (5.3)
Refused 6 (1.8) 1 (0.3) 3 (0.9)
Note: Numbers may not add up to the total n for the respondent group as participants could decline to answer question







Fig. 2 Log odds for selecting each factor, for each group
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Among adolescents and parents, the next most influential
factor in their decision to vaccinate following vaccine effect-
iveness was PCP recommendation. Adolescents were sig-
nificantly more likely to accept vaccines that came with a
strong PCP recommendation (“said it was very important”),
and significantly less likely to accept vaccines where the
PCP never talked to them about vaccines. But other posi-
tive or negative forms of recommendation did not impact
respondent choice. (Fig. 2b). Parent respondents were more
likely to choose a vaccine that came with either a weak
(“should think about getting vaccinated”) or a strong rec-
ommendation, and a strong recommendation significantly
influenced decisions over a weak recommendation. Similar
to adolescents, parents were significantly less likely to
accept vaccines where the PCP never talked to them about
vaccines. But other types of recommendations did not im-
pact respondent choice (Fig. 2c). Adults were significantly
more likely to choose a vaccine with a strong recommenda-
tion, and less likely to choose one with a recommendation
not to vaccinate, but other intermediate levels of recom-
mendation did not significantly influence preferences.
Using our model to predict vaccine uptake based on
hypothetical changes in the PCP recommendations pre-
sented in vaccine scenarios, we found that the percentage
of adults who accept a vaccine is estimated to significantly
increase from 47% if their PCP never talks about the vac-
cine, to 60% if their PCP strongly recommends the vaccine
(predicted probabilities and 95% CIs in Additional file 5:
Table S5). The increase in predicted uptake was even
greater among the other two respondent groups. Going
from a scenario without any PCP recommendation to a
strong PCP recommendation, probabilities of vaccine
acceptance increased from 48% to 70% among adoles-
cents, and from 55% to 77% among parents.
Other factors besides vaccine effectiveness, out-of-
pocket cost and PCP recommendation were less influen-
tial across all groups, and in many cases did not impact
preferences at all (Fig. 2a-c). Adult decisions were more
influenced by the risk of death without vaccination
versus other groups. Adolescents and parents were more
concerned than adults about the seriousness of the illness.
Parents were more concerned than other groups about
the length of time the vaccine had been available.
Demographics
Respondent characteristics had mixed effects across
subgroups (Table 3). There were no gender differences in
adult or adolescent decisions to accept a vaccine in the
survey. Among parents, mothers were less likely than
fathers to accept a vaccine for their child. Non-white
Table 3 Odds ratios for demographic variables* Indicates increased (OR > 1) or decreased (OR < 1) odds of respondent with
demographic variable shown accepting a vaccine shown in a profile compared to the reference group
Attribute Level Adults Adolescents Parents of adolescents
OR P-value OR P-value OR P-value
Respondent gender Male REF – REF – REF –
Female 0.98 0.912 1.12 0.584 0.64† 0.025
Median age category Below median REF – REF – REF –
At or greater than median age 1.11 0.595 0.67 0.055 0.70 0.073
Respondent education < Bachelor’s degree REF – – – REF –
Bachelor’s degree and higher 0.68 0.063 – – 1.33 0.156
Region Northeast REF – REF – REF –
Midwest 1.17 0.594 1.99 0.077 0.82 0.484
South 1.01 0.981 1.15 0.696 0.74 0.285
West 1.07 0.837 1.45 0.339 1.33 0.349
Race/ethnicity White, non-Hispanic REF – REF – REF –
Non-white, non-Hispanic 1.54 0.068 2.14† 0.001 2.33† < 0.001
Household income <$50,000/yr REF – REF – REF –
> = $50,000/yr 1.71† 0.012 0.62† 0.028 0.61 0.052
Employed Yes REF – – – REF –
No 1.05 0.831 – – 0.76 0.256
Side effect experience Yes REF – REF – REF –
No 2.33† < 0.001 1.49 0.073 1.66† 0.020
*Model also contained additional variables: Seriousness of illness, duration of illness, vaccine effectiveness, risk of illness without vaccination, risk of death without
vaccination, risk of severe side effects, length of time vaccine available, location, time, healthcare provider type, PCP recommendation, and cost after insurance
†Indicates that odds ratio is significantly different from 1 (p < 0.05)
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adolescents and parents were significantly (p < 0.05) more
likely to accept a vaccine, compared to white respondents
in those groups. Similarly, non-white adults appear more
likely to accept a vaccine (p = 0.07). Adult respondents
with a household income above $50,000 were significantly
more likely (p = 0.01) to accept a vaccine, but adolescents
above this income level were significantly less likely to
accept the vaccine (p = 0.03) and higher income parents
similarly appear less likely to accept the vaccine (p = 0.05).
Adults and parents without side effect experience were
significantly (p < 0.05) more likely to accept the vaccine
presented in the survey compared with those with
side effect experience. Similarly, adolescents without
side effect experience appear more likely to accept a
vaccine (p = 0.07). All other demographic characteris-
tics were not significantly associated with the decision
to accept the vaccine.
Sensitivity analyses
More than one third of respondents were either “vaccine
acceptors”, always accepting the profile presented, or
“vaccine rejecters”, always rejecting the profile. Seventeen
percent of adults, 24% of adolescents, and 34% of parents
always accepted the profiles shown (p < 0.05 for diffe-
rences across groups). Seventeen percent of adults, 14% of
adolescents, and 12% of parents always rejected the pro-
files shown (no significant differences between groups;
Additional file 6: Table S6). Sensitivity analyses that
excluded these respondents, as well as those that excluded
respondents who stated they were not confident in their
choices (11% adults, 11% adolescents, and 7% parents),
did not change our findings. Alternative model specifi-
cations that included variables for absolute risk reduction
due to vaccination were not a better fit for our data
(Additional file 7: Table S7).
Discussion
Improving recommended vaccine coverage for adults and
adolescents has been an ongoing public health challenge
in the United States. When deciding whether to vaccinate,
our results indicate that adults, adolescents, and parents
generally prioritize vaccine effectiveness, out-of-pocket
cost, and PCP recommendation. The out-of-pocket cost
and PCP recommendation attributes are important to
consider when designing vaccination programs because
they have the potential to be modified through health
policies.
Across all three populations, and particularly among
adults, we found out-of-pocket cost to be an important
predictor of whether the respondent accepted or declined
the vaccine. This emphasizes the importance of programs
like Vaccines for Children, and Public Health Service
Section 317 discretionary funding support for adolescents
and adults, respectively, which enable healthcare providers
to secure vaccines at no charge and vaccinate uninsured
and underinsured populations. Likewise, insurance
policies can ensure that vaccines remain affordable to
people of all ages and continued efforts should be
made to educate the general public about the inclusion of
vaccines in their health plans.
A strong PCP recommendation was shown to signifi-
cantly increase vaccine acceptance in all groups, highlight-
ing why healthcare providers should be encouraged to talk
about the value of vaccines during routine patient visits.
This is particularly true as we found that even a weak
recommendation to vaccinate only made parents, not
adults or adolescents, more likely to vaccinate. Other
recommendations or lack thereof, either had no impact
on preferences or influenced choices to not vaccinate.
These findings underscore the need for continued training
support for healthcare professionals, as they work to
increase vaccine acceptability among their patients.
Adults, adolescents and parents may prioritize diffe-
rent factors when making decisions about vaccines.
Parents were relatively more concerned about number of
years the vaccine had been available. Previous research
has shown that parents are more likely to refuse newer
vaccines, and express concerns that newer vaccines have
not been available long enough for them to trust [27, 28].
Our study indicates that parents may perceive a vaccine as
being “new” and be less likely to accept it for their child
for at least 5 years and may not fully trust the vaccine until
it has been on the market for much longer, potentially up
to 30 years. This highlights the need to educate parents
and encourage physicians to discuss the safety of vaccines
with parents in particular, especially for newer vaccines.
Also, compared to adults, adolescents were more con-
cerned with the seriousness and duration of the illness
when making a decision to be vaccinated. Adolescents
were more likely to choose vaccination if the illness lasted
longer (months vs. days), or restricted them from doing
their daily activities, whereas these factors did not in-
fluence adult decisions.
Previous studies on vaccine uptake have focused on
specific groups, such as pregnant women [29, 30], ethnic
minority and low-income groups, or specific vaccines
like HPV [7, 11, 12, 31], meningococcal [32], and in-
fluenza [29] vaccines. Our results are consistent with many
of these more narrowly focused studies, which found a
strong association between out-of-pocket cost, vaccine
effectiveness, provider recommendation, and vaccine
acceptance. This study adds the strength of a relatively
large national sample, a quantitative assessment of inter-
action between decision-making factors, and an important
understanding of how the relative importance these factors
vary between adults, adolescents, and parents.
This study has several limitations. Our national samples
are not representative in all respects. A low response rate,
Lavelle et al. Journal of Patient-Reported Outcomes            (2019) 3:51 Page 9 of 12
particularly for the adolescent group (21% response) may
impact results’ generalizability. Our analyses controlled for
important variables that may impact vaccine preferences,
including race/ethnicity, income and education. However,
there may be unmeasured characteristics in each group
that differ from national averages and may impact re-
sults. Sampling weights were not used in our analysis,
as the sample sizes were too small to reliably use post-
stratification weighting adjustments.
We asked respondents whether they would choose to
accept a hypothetical vaccine versus no vaccine, but
guidelines recommend that individuals receive numerous
vaccines, with more than one vaccine often offered in one
visit. Therefore, our scenarios which characterized vacci-
nation decisions as one-off choices may not accurately
describe the true decision-making context. In addition, by
focusing on a hypothetical vaccine and not a particular
one (e.g., HPV vaccine), we may have missed specific
factors that are important in certain decision-making
scenarios. We also asked respondents to imagine scenarios
where they would have to pay for a vaccine at the level
specified in the profile. However, most parents and adoles-
cents do not face co-pays for recommended vaccines, so
this may have impacted responses.
Additionally, we sought to understand how people
prioritize between twelve factors related to vaccination
decision-making, which emerged as important attributes
from the focus group. However, as pre-testing highlighted
the cognitive burden of considering all attributes at once,
we created partial profiles with eight attributes. Partial
profiles may introduce bias, although the direction of this
bias is not clear, and should be considered carefully, as
respondents consider their choices based on some attri-
butes without others. In these cases where there are a
large number of relevant attributes, choice experiments
may not be well suited to accommodate the complexity of
the decision-making process. These issues may have
contributed to the lack of expected natural ordering of the
preferences obtained from our results. As the field moves
forward, a best-worst scaling approach could be used to
first narrow down the number of attributes considered in
a choice task with many attributes identified as important
to the decision maker. In addition, we considered four at-
tributes that people may collectively think of as describing
the severity of illness (seriousness and duration of illness,
and the risk of illness and death) separately in the survey,
which may have diluted their combined importance.
And finally, the binary choice we used in our preference
survey is not representative of most choice experiments,
which typically ask respondents to choose between pairs
of profiles in a discrete choice experiment. This binary
choice format may have been underpowered to detect the
importance of attribute levels in influencing choices. The
sample size for the survey was determined based on a
previous survey design that was revised during pre-
testing, but without additional resources to increase the
sample size.
In addition, the logistic regression analysis used is
appropriate for these binary outcomes but does not
account for random choice error which is common in
choice experiments such as this one. There may also be
scale effects across the adult, adolescent, and parent
samples which cannot be directly evaluated in logistic
regression analyses using standard approaches. The
binary choice format, along with our partial profile design,
also prohibited us from identifying respondents who may
have answered all questions based on a particular attribute
(attribute dominance, e.g., lowest cost). However, other
sensitivity analyses we performed did not produce mark-
edly different results from our base case analysis. Analyses
of best-worst scaling results (not shown) indicate that
these two methods are complementary and produce
consistent results.
We did not build repeat profiles into the experimental
design to identify respondents whose choices suggested
a lack of attention or task comprehension. However,
sensitivity analyses that excluded respondents who
always accepted or rejected the vaccine, as well as who
stated they were not confident in their choices, did not
change our findings.
Conclusions
Our study found that adults, adolescents and parents
considered vaccine effectiveness, out-of-pocket cost, and
PCP recommendation as the most important factors
related to vaccination. They did not prioritize the risk of
illness, the risk of vaccine side effects, vaccination lo-
cation, or time for vaccination when choosing whether
to be vaccinated.
Low out-of-pocket costs and healthcare provider
recommendation may be effective levers to influence
vaccine uptake. Healthcare providers should be cognizant
of the strength of their recommendation and their role in
increasing vaccination coverage rates among adults and
adolescents. Healthcare policies and immunization pro-
grams should strengthen access to vaccines by ensuring
that out-of-pocket cost is not a barrier.
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